{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}],"title":"sCR"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"CR"},{"measurements":[{"groupId":"OG000","value":"12"}],"title":"PR"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"MR"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"NC"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"PD"}],"title":"After 4-month PAD treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}],"title":"sCR"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"CR"},{"measurements":[{"groupId":"OG000","value":"12"}],"title":"PR"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"MR"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"NC"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"PD"}],"title":"After ASCT"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}],"title":"sCR"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"CR"},{"measurements":[{"groupId":"OG000","value":"9"}],"title":"PR"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"MR"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"NC"},{"measurements":[{"groupId":"OG000","value":"4"}],"title":"PD"}],"title":"End of study"}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Evaluation of responses was performed every cycle. Responses were assessed according to the european group for blood and marrow transplantation（EBMT） criteria (An attempt will be made to collect data for the assessment of stringent complete response (sCR) if these data are available.). Other efficacy parameters including PFS and 1-year overall survival rate and overall survival will be evaluated by normal methodology. According to EBMT criteria, responses were assessed by changes in the level of the serum paraprotein and/or urinary light chain excretion.The specific assessment rules may refer to EBMT criteria for MM.","groups":[{"description":"Drug: Bortezomib, Adriamycin (Doxorubicin) /Epidoxorubicin(EPI), Dexamethasone.\n\nAfter received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators.\n\nPAD Followed by ASCT: Drug: Bortezomib, Bortezomib (1.3mg/m2, iv, on day 1, 4, 8, 11, of each 28 day cycle)\n\nDrug: Adriamycin (Doxorubicin) /EPI, Adriamycin (Doxorubicin) (9 mg/m2, iv, on days 1-4 of each 28 day cycle) or EPI (15mg/m2, iv, on days 1-4 of each 28 day cycle)\n\nDrug: Dexamethasone, Dexamethasone (20mg, iv, on days 1-4, 8-11of each 28 day cycle)\n\nAfter received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators.","id":"OG000","title":"PAD Followed by ASCT"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"At baseline, on day 28 of cycles 4, and after 4, 6, 12 and 18 months of follow-up","title":"Evaluation of Responses","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Participants"}